About Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 2006, and was acquired by Pfizer in April 2021. Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma. Amplyx Pharmaceuticals has raised $144.31 million across 20 funding rounds from investors including Pfizer, HHS and Arix Bioscience. The company has 15 employees. Its chief executive, as recorded, is Mike Grey. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Fungal. Its legal entity is Amplyx Pharmaceuticals Inc. Its competitors include Scynexis, Elion Therapeutics and Mycovia Pharmaceuticals; 2 of its 3 listed competitors have raised funding.
Company details
Amplyx Pharmaceuticals is US-based, clinical stage biopharma developing broad-spectrum small molecule fungal enzyme inhibitors. The companys lead compound, APX001 (completed Phase I trials) has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. APX001 targets the GWT1 enzyme required for glycophosphatidylinositol (GPI) anchor biosynthesis- this cellular process is required for the anchoring of proteins to both the fungal cell wall and cell membrane and is specific to fungi (not humans). By targeting this, the drug leads to errors in the cell wall of the fungi and their death.
- Headquarters San Diego, United States
- Employees 15
- Stage Acquired
- SectorsHealthcare
- Website amplyx.com
- Social LinkedIn
- Acquired by Pfizer (Apr 2021)
- Legal Name Amplyx Pharmaceuticals Inc
Funding Insights of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has successfully raised a total of $144.31M across 20 strategic funding rounds. The most recent funding activity was a Series C round of $91.33 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $144.31M
- Total Rounds 20
- Last Round Series C β $91.33M
- First Round $781,000
(Sep 2008)
- Investors Count 15
Latest 10 of 20 funding rounds of Amplyx Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $91.33M | Series C | β | Sofinnova Investments | |
| Aug 2017 | $1.46M | Grant | β | β | |
| Jul 2016 | $1.46M | Grant | β | β | |
| Feb 2016 | $8.7M | Series B | β | 3x5 Partners | β |
| Dec 2015 | $40.5M | Series B | β | RiverVest Venture Partners | |
| Aug 2015 | $1.5M | Series A | β | β | β |
| Feb 2014 | $225,000 | Grant | β | β | |
| Jul 2013 | $2.08M | Grant | β | β | |
| Mar 2013 | $697,056 | Grant | β | β | |
| Mar 2013 | $696,719 | Grant | β | β |
15 investors in total: 15 institutional.
Investors in Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, HHS and Arix Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
| rivervest.com | ||||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Life science companies are funded through venture capital investments. | lundbeckfonden.com | Copenhagen, Denmark | ||
Private investments are managed for institutional investors globally. | 3x5partners.com | United States | ||
| k4northwest.com | ||||
Tech & Life-Sciences focused VC Firm investing in the US | goldenseeds.com | New York, United States |
Investor details for Amplyx Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amplyx Pharmaceuticals
1 people are tracked at Amplyx Pharmaceuticals (1 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Mike Grey | CEO | Leadership |
Complete people profiles for Amplyx Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Amplyx Pharmaceuticals
4 dated milestones of Amplyx Pharmaceuticals across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Amplyx Pharmaceuticals is founded.
- Funding First funding round of $781K.
- Funding Latest funding round, Series C, of $91.3M.
- Exit Acquired by Pfizer.
Competitors of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Scynexis, Elion Therapeutics and Mycovia Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scynexis.com | 1999 | Jersey, United States | $62.65M | 50 | Developing glucan synthase inhibitors for the treatment of fungal infections. | |
| eliontx.com | 2024 | New York, United States | $81M | Therapeutics for invasive fungal infections are developed by Elion Therapeutics. | ||
| mycovia.com | 2018 | Durham, United States | Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment. |
Detailed competitors of Amplyx Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Amplyx Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amplyx Pharmaceuticals
Complete news archive for Amplyx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amplyx Pharmaceuticals
Amplyx Pharmaceuticals was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Amplyx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Mike Grey is the CEO of Amplyx Pharmaceuticals, as recorded in our data.
Amplyx Pharmaceuticals is a funded company, having raised a total of $144.31M across 20 funding rounds to date. The company's 1st funding round was a Grant of $696.72K, raised on Sep 2008.
Amplyx Pharmaceuticals has 15 employees.
Amplyx Pharmaceuticals is US-based, clinical stage biopharma developing broad-spectrum small molecule fungal enzyme inhibitors. The companys lead compound, APX001 (completed Phase I trials) has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. APX001 targets the GWT1 enzyme required for glycophosphatidylinositol (GPI) anchor biosynthesis- this cellular process is required for the anchoring of proteins to both the fungal cell wall and cell membrane and is specific to fungi (not humans). By targeting this, the drug leads to errors in the cell wall of the fungi and their death.
Amplyx Pharmaceuticals's top competitors include Scynexis, Elion Therapeutics and Mycovia Pharmaceuticals.
Amplyx Pharmaceuticals has 15 investors. Key investors include Pfizer, HHS, Arix Bioscience, Sofinnova, and NEA.
Amplyx Pharmaceuticals operates through Amplyx Pharmaceuticals Inc.
Yes. Amplyx Pharmaceuticals was acquired by Pfizer in April 2021.

